Why has the pharma industry and its talents lost interest in developing new antibiotics?
List view / Grid view
Filter the results
This August saw nine new green lights from the FDA, all small molecules, which makes up a third of the approvals this year.
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...